drugset
drugset / Trial / NCT05262413

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

NCT05262413 ↗

Phase 1/2 Unknown 60 enrolled Qilu Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1b, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of QL1706 plus lenvatinib in subjects with advanced RCC.

Timeline

Start
2022-02-28
Primary completion
2023-07-30
Completion
2024-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 14 mg Oral
Subject Lenvatinib Small molecule 20 mg Oral
Subject QL1706 Monoclonal antibody 5 mg/kg Intravenous

Indications

renal cell carcinoma